Literature DB >> 20483176

Heritability of acoustic startle magnitude, prepulse inhibition, and startle latency in schizophrenia and control families.

Wendy Hasenkamp1, Michael P Epstein, Amanda Green, Lisette Wilcox, William Boshoven, Barbara Lewison, Erica Duncan.   

Abstract

Prepulse inhibition (PPI) is an acoustic startle paradigm that has been used as an operational measure of sensorimotor gating. Many patients with schizophrenia have impaired PPI, and several lines of evidence suggest that PPI may represent a heritable endophenotype in this disease. We examined startle magnitude and latencies in 40 schizophrenia patients, 58 first-degree relatives of these patients, and 100 healthy controls. After removing low-startlers, we investigated PPI and startle habituation in 34 schizophrenia patients, 43 relatives, and 86 control subjects. Heritability analyses were conducted using a variance-component approach. We found significant heritability of 45% for PPI at the 60-ms interval and 67% for startle magnitude. Onset latency heritability estimates ranged between 39% and 90% across trial types, and those for peak latency ranged from 29% to 68%. Heritability of startle habituation trended toward significance at 31%. We did not detect differences between controls and either schizophrenia patients or their family members for PPI, startle magnitude, or habituation. Startle latencies were generally longer in schizophrenia patients than controls. The heritability findings give impetus to applying genetic analyses to PPI variables, and suggest that startle latency may also be a useful measure in the study of potential endophenotypes for schizophrenia. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20483176      PMCID: PMC2902662          DOI: 10.1016/j.psychres.2009.11.012

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  74 in total

Review 1.  Variance component methods for detecting complex trait loci.

Authors:  J Blangero; J T Williams; L Almasy
Journal:  Adv Genet       Date:  2001       Impact factor: 1.944

2.  Effects of smoking on acoustic startle and prepulse inhibition in humans.

Authors:  E Duncan; S Madonick; S Chakravorty; A Parwani; S Szilagyi; T Efferen; S Gonzenbach; B Angrist; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

3.  Clinical and sensorimotor gating effects of ketamine in normals.

Authors:  E J Duncan; S H Madonick; A Parwani; B Angrist; R Rajan; S Chakravorty; T R Efferen; S Szilagyi; M Stephanides; P B Chappell; S Gonzenbach; G N Ko; J P Rotrosen
Journal:  Neuropsychopharmacology       Date:  2001-07       Impact factor: 7.853

Review 4.  The effect of neuroleptic medication on prepulse inhibition in schizophrenia patients: current status and future issues.

Authors:  A O Hamm; A I Weike; H T Schupp
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 5.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

6.  Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics.

Authors:  Veena Kumari; William Soni; Tonmoy Sharma
Journal:  Schizophr Res       Date:  2002-05-01       Impact factor: 4.939

7.  Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia.

Authors:  Katja Ludewig; Mark A Geyer; Mario Etzensberger; Franz X Vollenweider
Journal:  Schizophr Res       Date:  2002-05-01       Impact factor: 4.939

8.  Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits.

Authors:  K S Cadenhead; N R Swerdlow; K M Shafer; M Diaz; D L Braff
Journal:  Am J Psychiatry       Date:  2000-10       Impact factor: 18.112

Review 9.  Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research.

Authors:  Veena Kumari; Tonmoy Sharma
Journal:  Psychopharmacology (Berl)       Date:  2002-06-05       Impact factor: 4.530

10.  Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission.

Authors:  William Perry; David Feifel; Arpi Minassian; Indira Bhattacharjie; David L Braff
Journal:  Am J Psychiatry       Date:  2002-08       Impact factor: 18.112

View more
  29 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

Review 3.  Endophenotype best practices.

Authors:  William G Iacono; Stephen M Malone; Scott I Vrieze
Journal:  Int J Psychophysiol       Date:  2016-07-27       Impact factor: 2.997

4.  Meta-Analysis of Sensorimotor Gating Deficits in Patients With Schizophrenia Evaluated by Prepulse Inhibition Test.

Authors:  Rodrigo San-Martin; Leonardo Andrade Castro; Paulo Rossi Menezes; Francisco José Fraga; Priscyla Waleska Simões; Cristiane Salum
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

5.  Toxoplasma gondii exposure affects neural processing speed as measured by acoustic startle latency in schizophrenia and controls.

Authors:  Bradley D Pearce; Sydney Hubbard; Hilda N Rivera; Patricia P Wilkins; Marylynn C Fisch; Myfanwy H Hopkins; Wendy Hasenkamp; Robin Gross; Nancy Bliwise; Jeffrey L Jones; Erica Duncan
Journal:  Schizophr Res       Date:  2013-08-13       Impact factor: 4.939

6.  Heritability of acoustic startle magnitude and latency from the consortium on the genetics of schizophrenia.

Authors:  Tiffany A Greenwood; Neal R Swerdlow; Joyce Sprock; Monica E Calkins; Robert Freedman; Michael F Green; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Keith H Nuechterlein; Allen D Radant; Jeremy M Silverman; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff; Erica Duncan
Journal:  Schizophr Res       Date:  2020-11-12       Impact factor: 4.939

7.  Between-site reliability of startle prepulse inhibition across two early psychosis consortia.

Authors:  Kristin S Cadenhead; Jean Addington; Tyrone D Cannon; Barbara A Cornblatt; Camilo de la Fuente-Sandoval; Dan H Mathalon; Diana O Perkins; Larry J Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Peter Bachman; Ayse Belger; Ricardo E Carrión; Franc C L Donkers; Erica Duncan; Jason Johannesen; Pablo León-Ortiz; Gregory Light; Alejandra Mondragón; Margaret Niznikiewicz; Jason Nunag; Brian J Roach; Rodolfo Solís-Vivanco
Journal:  Neuroreport       Date:  2013-08-07       Impact factor: 1.837

8.  Heritability and molecular genetic basis of acoustic startle eye blink and affectively modulated startle response: a genome-wide association study.

Authors:  Uma Vaidyanathan; Stephen M Malone; Michael B Miller; Matt McGue; William G Iacono
Journal:  Psychophysiology       Date:  2014-12       Impact factor: 4.016

9.  Acoustic startle reduction in cocaine dependence persists for 1 year of abstinence.

Authors:  Sarah Corcoran; Seth D Norrholm; Bruce Cuthbert; Maya Sternberg; Jeff Hollis; Erica Duncan
Journal:  Psychopharmacology (Berl)       Date:  2010-12-16       Impact factor: 4.530

10.  Low startle magnitude may be a behavioral marker of vulnerability to cocaine addiction.

Authors:  Marina G Wheeler; Erica Duncan; Michael Davis
Journal:  Synapse       Date:  2016-11-18       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.